MET: Difference between revisions
(Created page with "MET is a gene that encodes for a receptor tyrosine kinase known as hepatocyte growth factor receptor (HGFR). This protein plays a crucial role in cell growth, survival, and regeneration. Abnormal activation of MET, through mutations, amplifications, or overexpression, is associated with various cancers, including non-small cell lung cancer, renal cell carcinoma, and gastric cancer. Such alterations can lead to uncontrolled cell proliferation and metastasis. Detecting MET...") |
No edit summary |
||
| Line 1: | Line 1: | ||
MET is a gene that encodes for a receptor tyrosine kinase known as hepatocyte growth factor receptor (HGFR). This protein plays a crucial role in cell growth, survival, and regeneration. Abnormal activation of MET, through mutations, amplifications, or overexpression, is associated with various cancers, including non-small cell lung cancer, renal cell carcinoma, and gastric cancer. Such alterations can lead to uncontrolled cell proliferation and metastasis. Detecting MET abnormalities in | MET is a gene that encodes for a receptor tyrosine kinase known as hepatocyte growth factor receptor (HGFR). This protein plays a crucial role in cell growth, survival, and regeneration. Abnormal activation of MET, through mutations, amplifications, or overexpression, is associated with various cancers, including non-small cell lung cancer, renal cell carcinoma, and gastric cancer. Such alterations can lead to uncontrolled cell proliferation and metastasis. Detecting MET abnormalities in tumours is essential for guiding targeted therapy, as MET inhibitors can block the aberrant signaling pathways, effectively slowing or stopping tumour growth. Understanding MET's role in cancer biology allows for personalized treatment strategies, offering improved outcomes and tailored therapies for patients with MET-driven cancers. | ||
Latest revision as of 14:23, 27 August 2024
MET is a gene that encodes for a receptor tyrosine kinase known as hepatocyte growth factor receptor (HGFR). This protein plays a crucial role in cell growth, survival, and regeneration. Abnormal activation of MET, through mutations, amplifications, or overexpression, is associated with various cancers, including non-small cell lung cancer, renal cell carcinoma, and gastric cancer. Such alterations can lead to uncontrolled cell proliferation and metastasis. Detecting MET abnormalities in tumours is essential for guiding targeted therapy, as MET inhibitors can block the aberrant signaling pathways, effectively slowing or stopping tumour growth. Understanding MET's role in cancer biology allows for personalized treatment strategies, offering improved outcomes and tailored therapies for patients with MET-driven cancers.
